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ARTICLE
A non-conserved amino acid variant regulates
differential signalling between human and mouse
CD28
Nicla Porciello1, Paola Grazioli2, Antonio F. Campese3, Martina Kunkl1, Silvana Caristi1, Marta Mastrogiovanni1,
Michela Muscolini4, Francesca Spadaro5, Cédric Favre6,7, Jacques A. Nunès 6 Aldo Borroto
8, Balbino Alarcon8, Isabella Screpanti3 & Loretta Tuosto1
CD28 superagonistic antibodies (CD28SAb) can preferentially activate and expand immu-
nosuppressive regulatory T cells (Treg) in mice. However, pre-clinical trials assessing
CD28SAbs for the therapy of autoimmune diseases reveal severe systemic inﬂammatory
response syndrome in humans, thereby implying the existence of distinct signalling abilities
between human and mouse CD28. Here, we show that a single amino acid variant within the
C-terminal proline-rich motif of human and mouse CD28 (P212 in human vs. A210 in mouse)
regulates CD28-induced NF-κB activation and pro-inﬂammatory cytokine gene expression.
Moreover, this Y209APP212 sequence in humans is crucial for the association of CD28 with
the Nck adaptor protein for actin cytoskeleton reorganisation events necessary for CD28
autonomous signalling. This study thus unveils different outcomes between human and
mouse CD28 signalling to underscore the importance of species difference when transferring
results from preclinical models to the bedside.
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CD28 is an important co-stimulatory molecule for T lym-phocytes, which delivers signals that complement T cellreceptor (TCR) in both qualitative and quantitative
manners, thus promoting high levels of cytokines, T cell pro-
liferation, survival and differentiation. During T: antigen pre-
senting cell (APC) encounter, CD28 binds to B7.1/CD80 and/or
B7.2/CD86 co-stimulatory molecules, expressed on the surface of
APCs (for example, macrophages, dendritic cells, and B lym-
phocytes), thus enhancing the close contact between T cells and
APCs and mediating the actin cytoskeleton rearrangement events
required for the generation of a dynamic platform at the
immunological synapse, where many signalling molecules are
recruited and protected from phosphatases1. Studies have also
evidenced the ability of CD28 to function in a TCR-independent
manner and to deliver unique signals regulating several bio-
chemical events2,3. For instance, in the human system,
CD28 stimulation by either agonistic antibodies or B7 molecules
induces the recruitment of several signalling proteins4–6 that in
turn cooperate to activate a non-canonical NF-κB2-like cascade7,8
leading to the upregulation of pro-inﬂammatory cytokine/che-
mokine genes in healthy individuals as well as in multiple
sclerosis (MS) and type 1 diabetes (T1D) patients9,10.
Until 2006, the signalling properties of CD28 between rodent
(mouse and rat) and human were considered rather similar and,
for several years, in vivo mouse models have been used for study
the function of CD28 costimulation in health and immune dis-
eases. Thus, when CD28 superagonistic antibodies (CD28SAb)
were discovered to preferentially activate and expand immuno-
suppressive regulatory T (Treg) cells11, pre-clinical experiments
have been performed to evaluate the potential use of these
CD28SAbs to ameliorate the onset, progression, and clinical
course of human autoimmune diseases. However, when a
humanised CD28SAb (TGN1412) was administered to volunteers
on March 2006, the phase I clinical trial turned in a catastrophe,
because this antibody induced a rapid and massive cytokine
production (for example, IFN-γ, IL-1, IL-6, and TNF), thus
causing a severe systemic inﬂammatory response syndrome12.
Altogether, the above-reported data evidenced that the translation
of experimental results from mice to humans could determine
dramatic effects, thus suggesting the existence of differences in
CD28 signalling capabilities between human and mouse13,14.
CD28 signalling properties rely on the composition of its small
cytoplasmic domain (41 aa), where three important motifs have
been identiﬁed: one N-terminal YMNM motif and two proline-
rich motifs that upon CD28 engagement induce protein recruit-
ment through their SH2 and/or SH3 domains2. By comparing the
sequence of the cytoplasmic tail of CD28 between human and
mouse, a single amino acid variant within the C-terminal proline-
rich motif was found: P212 in human CD28 (hCD28) (PYAPP212)
vs. A210 (PYAPA210) in mouse.
In this study, we analyse the signalling pathways and bio-
chemical mediators activated upon agonistic and superagonistic
stimulation of primary CD4+ T cells and investigate the role of
the single P to A substitution within the cytoplasmic tail of
human and mouse CD28. Our data provide evidence that P212
residue within the C-terminal proline-rich motif of hCD28 is
essential for delivering pro-inﬂammatory signals and the natural
P to A substitution, in mouse CD28 can, at least in part, explain
the different signalling capabilities of CD28 in human and
mouse.
Results
CD28 pro-inﬂammatory signals in human but not mouse
T cells. We and others have reported that, in human primary
CD4+ T cells, CD28 stimulation by B7 molecules, or agonistic
Abs, or CD28SAbs, in the absence of TCR ligation, induces the
expression of pro-inﬂammatory cytokines and chemo-
kines7,9,10,14. Conversely, in the mouse system, CD28 stimulation
alone did not exhibit any pro-inﬂammatory activity13, and
CD28SAbs, instead, preferentially activated and expanded
immunosuppressive Treg cells11.
We ﬁrst performed a kinetic analysis of the relevant pro-
inﬂammatory cytokines and chemokines induced by stimulating
human CD4+ T cells with either agonistic (CD28.2) or super-
agonistic (ANC28.1) Abs. The results reported in Supplementary
Fig. 1 evidenced that almost cytokines reached a peak of
expression after 6 h and returned to a basal level after 24 h from
stimulation (Supplementary Fig. 1a–c). By contrast, TNF
expression peaked at 1 h and returned to a basal level after 6 h
from stimulation (Supplementary Fig. 1d).
The comparison of cytokine gene expression extent in CD4+
T cells from human and mouse evidenced high levels of TNF,
IFN-γ, IL-1β, IL-6, IL-8, and IL-2 in human CD4+ T stimulated
by CD28SAb compared to mouse CD4+ T cells, which
exhibited only a signiﬁcant (p < 0.01, by Mann–Whitney test)
upregulation of IL-2 mRNA (Fig. 1a–f), as previously
reported11,15. The kinetic (Supplementary Fig. 2a, c, e) and
dose response analysis of cytokine gene expressions (Supple-
mentary Fig. 2b, d, f) induced by stimulating human or mouse
CD4+ T cells with different concentrations of crosslinked
CD28SAbs revealed that, in mouse CD4+ T cells, D665 Ab did
not induce any signiﬁcant pro-inﬂammatory cytokine gene
expressions even at the higher dose and after 6 h from
stimulation. Conversely, the lowest concentration of human
ANC28.1 Ab strongly upregulated TNF, IL-6, and IFN-γ
mRNAs (Supplementary Fig. 2).
Consistently with our previous ﬁndings7,9, stimulation of
human CD4+ T cells with agonistic CD28.2 Ab induced
signiﬁcant and strong increase of IL-6 (p < 0.001, by
Mann–Whitney test) and IL-8 (p < 0.01, by Mann–Whitney test)
mRNA levels (Fig. 1g). By contrast, stimulation of mouse CD4+
T cells with agonistic 37.51 Ab did not induce any signiﬁcant
cytokine mRNA expression (Fig. 1h). Interestingly, engagement
of CD28 by its natural ligand B7.1/CD80 was also able to induce
signiﬁcant (p < 0.05, by Student’s t-test) IL-8 secretion, as the
agonistic CD28.2 Abs (Supplementary Fig. 3a). These data
suggest that hCD28 has an intrinsic capability to trigger pro-
inﬂammatory signals.
The higher levels of pro-inﬂammatory cytokines and chemo-
kines induced by CD28 triggering in human CD4+ T cells,
compared to mouse CD4+ T cells, could not be related to
different stimulation activities of the agonistic and/or super-
agonistic Abs. For instance, the co-engagement of CD3 and CD28
induced comparable levels of IL-2 mRNAs in both human and
mouse CD4+ T cells (Fig. 1i). On the contrary, a high
upregulation of IFN-γ mRNA was detected only in CD3/CD28-
stimulated human CD4+ T cells (Fig. 1j). Moreover, super-
agonistic human ANC28.1 and mouse D665 Abs efﬁciently
induced the expansion of Treg cells (Fig. 2a). Finally, the high
pro-inﬂammatory activity of hCD28 was not related to the
preferential stimulation of effector/memory T cells, as proposed
by other researchers16,17. Indeed, even if the mean percentage of
human naïve T cells was lower than mouse (Supplementary
Fig. 3b–e), no signiﬁcant differences in cytokine gene expression
were observed upon stimulation of human naïve or effector/
memory T cells with either agonistic or superagonistic anti-CD28
Abs (Fig. 2b–f).
These data evidence that the pro-inﬂammatory CD28
behaviour is independent of the differentiation status of
T cells, but is a signalling signature of the human costimulatory
receptor.
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P212 residue regulates hCD28 pro-inﬂammatory functions.
CD28 signalling capabilities rely on the sequence of its small
cytoplasmic domain that, in both mouse and hCD28, contains
important motifs that bind several signalling molecules2. The
comparison of the sequence in the cytoplasmic tail of CD28
between human and mouse reveals a single amino acid variant
within the C-terminal proline-rich motif: P212 in hCD28 vs. A210
in mouse (Fig. 3a). This P residue is conserved in higher primates
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Fig. 1 CD28 stimulation strongly upregulates pro-inﬂammatory cytokine and chemokine gene expressions in human but not in mouse CD4+ T cells. mRNA
levels of splenic CD4+ T cells from n= 13 mice or human peripheral blood CD4+ T cells stimulated for 1 h or 6 h with 2 μg ml−1 isotype control mAb (Ig) or
crosslinked agonistic Abs (human CD28.2 or mouse 37.51) or CD28SAbs (human ANC28.1 or mouse D665), or anti-CD3 (human UCHT1 or mouse 145-
2C11) plus anti-CD28 (human CD28.2 or mouse 37.51) Abs. a TNF (1 h stimulation). b IL-6 (1 h stimulation). c IFN-γ (1 h stimulation). d IL-2 (6 h
stimulation). e IL-1β (1 h stimulation). f IL-8 (6 h stimulation). Median values: TNF (n= 7), ANC28.1= 102.3 vs. D665= 2.77; IL-6 (n= 6), ANC28.1= 69.7
vs. D665= 8.5; IFN-γ (n= 7), ANC28.1= 22.5 vs. D665= 1.94; IL-2 (n= 6), ANC28.1= 214 vs. D665= 176; IL-1β (n= 6), ANC28.1= 34.0; IL-8 (n= 6),
ANC28.1= 13.1. g IL-6 (n= 8, median= 138.9), IL-8 (n= 9, median= 19.5), IFN-γ (n= 3, median= 6.8), and IL-2 (n= 5, median= 1.1) mRNAs levels upon
6 h stimulation of human CD4+ T cells with isotype control Ig or crosslinked human CD28.2. h IL-6 (median= 6.6), IFN-γ (median= 4.3), IL-2 (median=
0.8), and TNF (median= 2.6) mRNAs levels upon 6 h stimulation of murine CD4+ T cells with isotype control Ig or crosslinked mouse 37.51. i Human IL-2
(n= 8, median= 36.6) and mouse IL-2 (median= 40.8), j human IFN-γ (n= 7, median= 51.1) and mouse IFN-γ (median= 2.4) mRNA levels upon 6 h
stimulation of CD4+ T cells with isotype control Ig or crosslinked anti-CD3 plus anti-CD28 Abs. All mRNAs were measured by real-time PCR and values,
normalised to GAPDH (human) or RLP32 (mouse), expressed as arbitrary units (AU) or fold induction (F.I.). Lines represent median values and statistical
signiﬁcance was calculated by Mann–Whitney test. Asterisks indicate *p < 0.05, **p < 0.01, ***p < 0.001, calculated on cells stimulated with isotype control Ig
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(for example, gorilla, macaque, and chimpanzee) but not in lower
mammals (for example, mouse, rat, rabbit, dog, and cat).
To verify if P212 within the C-terminal proline-rich motif of
hCD28 could account for the functional differences observed with
respect to mouse CD28, the CH7C17 CD28-negative Jurkat T cell
line (Fig. 3b) was reconstituted with hCD28 WT (hCD28WT) or
hCD28 mutant containing a P212 to A substitution within the C-
terminal proline-rich motif (Fig. 3a). In Jurkat cells expressing
comparable levels of CD28 WT or CD28P212A mutant (Fig. 3c),
cytokine mRNA levels were strongly reduced by P212A mutation
following stimulation with superagonistic ANC28.1 (Fig. 3d–f) or
agonistic CD28.2 Abs (Fig. 3g). Moreover, stimulation of
CH7C17 Jurkat cells expressing mouse CD28 WT (mCD28WT,
Supplementary Fig. 4b) with either superagonistic D665 or
agonistic 37.51 Abs did not induce any signiﬁcant increase of pro-
inﬂammatory cytokines (Supplementary Fig. 4d–f). On the
contrary, stimulation of murine EL-4 T cells expressing hCD28
WT (Supplementary Fig. 4c) with CD28.2 Ab strongly upregu-
lated IL-6 (Supplementary Fig. 4g). Consistently with the pivotal
role of NF-κB3[,7 in regulating hCD28-induced expression of pro-
inﬂammatory cytokines/chemokines2,9, NF-κB transcriptional
activity was also strongly impaired in both mCD28WT and
hCD28P212A cells following CD28 engagement by either APC
(Fig. 4e, g), expressing comparable levels of human (Fig. 4b) or
mouse B7.1 (Fig. 4c), or agonistic/superagonistic Abs (Fig. 4f, h)
compared to hCD28WT. Interestingly, the stimulation of
CH7C17 cells expressing mCD28 containing an A210 to P
substitution within the C-terminal proline-rich motif (Fig. 4a, c)
with agonistic 37.51 (Fig. 4i, j) or superagonistic D665 (Fig. 4k)
Abs strongly increased NF-κB transcriptional activity (Fig. 4i),
total tyrosine phosphorylation (Fig. 4j), and IL-8 mRNA levels
(Fig. 4k) compared to mCD28WT, thus supporting the relevance
of YAPP sequence in CD28 autonomous signalling. Finally,
hCD28P212A mutant also displayed a signiﬁcant (p < 0.01, by
Student’s t-test) reduction of NF-AT transcriptional activity
(Supplementary Fig. 5a) and IL-2 gene expression (p < 0.05, by
Student’s t-test) following TCR/CD28 co-engagement (Supple-
mentary Fig. 5b).
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Altogether these data suggest that the pro-inﬂammatory
properties of hCD28 likely rely on its intrinsic capability to
activate NF-κB and the absence of the P residue in the C-terminal
proline-rich motif of mouse CD28 might explain the failure of
mouse CD28 to induce both NF-κB activity and pro-
inﬂammatory cytokine/chemokine gene expression.
Human CD28 but not mouse binds to Nck. We next proceeded
to the analysis of proteins co-precipitating with CD28 in both
human and mouse T lymphocytes. Based on our previous data,
we speciﬁcally looked at the p85 adaptor subunit of PI3K, Vav1,
and Nck6. An association of CD28 with Vav1 was observed in
both human (Fig. 5a, upper panel) and mouse CD4+ T cells
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stimulated with B7-expressing cells (Fig. 5c, upper panel). On the
contrary, a strong association of CD28 with Nck was observed in
human (Fig. 5a, middle panel), but not in mouse CD4+ T cells
(Fig. 5c, middle panel), following B7.1/CD80 engagement. Both
human and mouse CD28 efﬁciently associated with the p85 adaptor
subunit of PI3K following stimulation with B7.1/CD80-expressing
APC (Fig. 5b, d, middle panels) or with agonistic anti-CD28 Abs
(Supplementary Fig. 9a). The differential association of Vav1 and
Nck with human and mouse CD28 was not due to differences in the
amounts of proteins, since human and mouse CD4+ T cells express
comparable levels of Vav1 and Nck (Fig. 5e).
These data suggest that the binding to Nck, an adaptor
molecule that plays a crucial role in the remodelling of actin
cytoskeleton events regulating T lymphocyte signalling and
activation18, may contribute to the different signalling capabilities
observed between human and mouse CD28.
P212 regulates CD28-induced actin cytoskeleton reorganisa-
tion. Most of the CD28-mediated signalling functions rely on its
intrinsic ability to regulate the remodelling of actin cytoskeleton
necessary for the initiation of autonomous signalling6,8. Thus, we
next analysed if hCD28 engagement by B7 could induce Vav1 and
Nckβ recruitment and the relevance of P212 residue. Confocal
microscopy analyses revealed that hCD28 stimulation by B7.1/
CD80-expressing cells (B7) induced both Vav1 (Fig. 6) and Nckβ
recruitment (Fig. 7), as well as the polarisation and accumulation
of F-actin at the T: APC interface (Figs. 6, 7). P212A substitution
of hCD28 strongly impaired the recruitment of Vav1 and Nckβ as
well as F-actin accumulation at the T-APC interface (Figs. 6, 7),
without affecting conjugate formation (Supplementary Fig. 6b).
The initial analyses of Vav1 recruitment and actin polymerisation
in CH7C17 cells reconstituted with mouse CD28 (mCD28)
revealed a signiﬁcant reduction (p < 0.05, by Student’s t-test) of
both Vav1 recruitment and F-actin polarisation (Supplementary
Fig. 6a). However, the number of conjugates between mCD28 and
B7.1/CD80-expressing Raw 264.7 cells was too low to gain a
statistical signiﬁcance (Supplementary Fig. 6b). Thus, we gener-
ated chimeric CD28 molecules containing the extracellular and
transmembrane domains of hCD28 and the cytoplasmic tail of
mouse CD28 WT or mouse CD28 mutant (A210P), where the A
within the PYAPA210 sequence was converted to P, as the human
one (YAPP212). In this way, the number of T: APC conjugates
reached the statistical signiﬁcance for performing confocal ana-
lyses (Supplementary Fig. 6b). Interestingly, the conjugation of
chimera CD28 WT, containing hCD28 extracellular domain and
mouse cytoplasmic domain, with cells expressing human B7.1/
CD80, failed to recruit Vav1 (Fig. 6 and Supplementary Fig. 7)
and Nckβ (Fig. 7 and Supplementary Fig. 7), as well as to polarise
F-actin at the T: APC contact zone (Figs. 6, 7 and Supplementary
Fig. 7). A210P mutation within the C-terminal proline-rich motif
of mouse CD28 signiﬁcantly restored Vav1 (Fig. 6 and Supple-
mentary Fig. 7), Nckβ (Fig. 7 and Supplementary Fig. 7), and F-
actin accumulation at the T: APC interface (Figs. 6, 7 and Sup-
plementary Fig. 7).
Altogether, these data evidenced that P212 residue within the
human C-terminal proline-rich motif of CD28 is pivotal for
recruiting the molecules regulating cytoskeleton reorganisation
and the lack of this P residue within the C-terminal proline-rich
motif of mouse CD28 may in part explain the inability of mouse
CD28 to function as a TCR-independent signalling unit.
CD28 signalling functions depend on the SH2 domain of Nck.
P212 residue within the C-terminal proline-rich motif of hCD28
does not affect the proline consensus motif (PYAPP212) of CD28,
but it may affect a SH2 binding consensus sequence
(Y209APP212). Both Nck18 and Vav119 contains a SH2 domain
that may potentially bind phosphorylated YAPP sequence within
hCD28 and both proteins can bind each other in a SH3-
dependent manner20. Our ex vivo data on the loss of Nck binding
to mouse CD28 (Fig. 5) strongly support a role for the SH2
domain of Nck in the recruitment of Nck, Vav1, and in F-actin
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Fig. 5 Nck binds to human but not mouse CD28. a, b Human primary CD4+
T cells were stimulated for 5 min with B7-negative (−) or Dap3/B7
(B7) cells and anti-CD28 IP were performed on cellular extracts. Anti-Vav,
anti-Nck, anti-p85 PI3K, and anti-CD28 western blottings were performed
on anti-CD28 IP or total lysates (TL). Data represent one of three
independent experiments. c, d CD4+ T cells isolated from murine spleen (n
= 10) were pooled and stimulated for 5 min with with B7-negative (−) or
B7.1-expressing RAW (B7) cells and anti-CD28 IP were performed on
cellular extracts. Anti-Vav, anti-Nck, anti-p85 PI3K, and anti-CD28 western
blottings were performed on anti-CD28 IP or total lysates (TL). The
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polarisation. To verify this hypothesis, we co-expressed Cherry-
Vav1 together with GFP-Nckβ WT or R311Q domain or W149K
mutant within the SH3.2 domain in JCH7C17 cells expressing
hCD28 WT. The R311Q and W149K mutations abrogate the
interaction of Nck SH2 and SH3 domains with phosphotyrosine
and proline, respectively21. Confocal analyses revealed that both
Vav1 and Nckβ were efﬁciently co-recruited and polarised with F-
actin at the T: APC contact zone following stimulation with B7.1/
CD80-positive (B7+) cells (Fig. 8). On the contrary Nckβ R311Q
mutant failed to recruit both Nckβ and Vav1 at the T: APC
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Fig. 6 P212 within the C-terminal proline-rich motif of human CD28 is essential for Vav1 recruitment and actin polymerisation. a hCD28WT or hCD28P212A
or chimera containing the extracellular and transmembrane domain of human CD28 and the cytoplasmic tail of mouse CD28 (Chimera CD28WT) or
mouse CD28 mutant (Chimera CD28A210P) were transfected with 20 μg of GFP-Vav1 (green) and then stimulated for 15 min in the absence (Ctr) or
presence of Dap/B7 cells (B7). After ﬁxing and permeabilisation F-actin was stained with 633-conjugated phalloidin (blue) and analysed by confocal
microscopy. The scale bar represents 10 μm. b, c The relative recruitment index (RRI) of Vav1 (b) and F-actin (c) was calculated as described in Methods
and represents the mean ± SD of 15 conjugates analysed in each group. Mean values: Vav, hCD28WT= 3.6 ± 1.6, hCD28P212A= 1.3 ± 0.24, Chimera
CD28WT= 1.14 ± 0.2, Chimera CD28A210P= 2.33 ± 0.9; F-actin, hCD28WT= 8.65 ± 3.6, hCD28P212A= 2.2 ± 0.9, Chimera CD28WT= 2.9 ± 1, Chimera
CD28A210P= 7.6 ± 3.8. Asterisks **p < 0.01, ***p < 0.001 calculated by Student’s t-test compared with hCD28WT. The results are representative of three
independent experiments
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interface (Fig. 8a, b) and to induce actin rearrangement (Fig. 8a,
c). No differences in Vav1, Nckβ recruitment, and F-actin
polarisation were observed by expressing the Nckβ W149K
mutant within the SH3.2 domain (Fig. 8) or a Vav1 R696A mutant
within the EKKAFR sequence (Fig. 9), which has been described
to impair Vav1 SH2 binding ability22. Moreover, although exo-
genously expressed Vav1 (Supplementary Fig. 8a) and Nck
(Supplementary Fig. 8b) could associate with hCD28 following
stimulation with B7.1/CD80-expressing APC, hCD28
preferentially co-precipitated with Nck, when both Nck and Vav1
were co-expressed (Supplementary Fig. 8c).
Finally, we analysed the role of Nck recruitment and actin
polymerisation in CD28 signalling functions. The overexpression
of Nckβ R311K in either CH7C17 Jurkat cells expressing
hCD28WT (Fig. 10a, g) or human primary CD4+ T cells
(Fig. 10b) as well as treatment with cytochalasin D (Fig. 10c–f), a
known actin polymerisation inhibitor, strongly impaired CD28-
induced NF-κB transcriptional activity (Fig. 10a) and pro-
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inﬂammatory cytokine expression (Fig. 10b–e), as well as CD28/
TCR-induced IL-2 gene expression (Fig. 10f) and NF-AT
transcriptional activity (Fig. 10g).
Altogether, these data strongly suggest that the natural P to A
substitution within the C-terminal proline-rich motif of mouse
CD28 causes the loss of a tyrosine binding motif (YAPP) for the
SH2 of Nck, thus impairing the cooperative activity of Vav1 and
Nck that is essential for optimal actin cytoskeleton rearrangement
and the activation of downstream signalling pathways23.
Discussion
Since its discovery, it has becoming clear that CD28 may function
as a TCR-independent signalling unit that delivers biochemical
signals inducing several gene expression programmes in T lym-
phocytes. In 1997, Hünig research group described a class of
superagonistic CD28-speciﬁc antibody (SAbs) able to induce, in
rat, proliferation of T cells without the need for TCR engage-
ment24. These non-conventional antibodies bind exclusively to
the laterally exposed C″D loop of the immunoglobulin-like
domain of CD28 in a parallel manner, whereas conventional,
agonistic Abs recognise an epitope close to the binding site for the
natural CD80/CD86 ligands, thus suggesting that different
topology of bound Abs may explain their different stimulatory
capabilities. The same group demonstrated that in vitro and
in vivo treatment with CD28SAbs of WT mouse or mouse suf-
fering of experimental autoimmune encephalomyelitis (EAE), an
animal model for human MS, preferentially activates and expands
immunosuppressive Treg cells that, upon adoptive transfer,
protect recipient mice from EAE15. When in March 2006, after
three sets of pre-clinical data, the intravenous injection of a
humanised CD28SAb (TGN1412) in six healthy young men
induced a strong cytokine-release syndrome12, the entire scien-
tiﬁc community tried to understand why the pre-clinical studies
had failed to predict the cytokine storm. Despite several efforts to
explain the failure of the hCD28 trial13,14,16,17,25, the molecular
players of the different outcomes between human and mouse
CD28 remain still unknown. Here, we compared the molecular
and biochemical events elicited following human and mouse
CD28 stimulation by natural ligands, agonistic or superagonistic
antibodies, thus evidencing the existence of different
CD28 signalling properties between humans and mice.
One of the main differences between human and mouse CD28
relies on the ability of hCD28 to deliver TCR-independent signals
regulating pro-inﬂammatory cytokine and chemokine gene
expression7,9,10,14. This unique intrinsic capability of hCD28 to
trigger pro-inﬂammatory signals is elicited by either natural B7
ligands7 (Supplementary Fig. 3a), agonistic Abs9, and in a more
pronounced fashion by CD28SAb14 (Fig. 1). Conversely,
CD28 stimulation of mouse CD4+ T cells with agonistic Abs does
not induce any pro-inﬂammatory cytokine gene expression and
CD28SAbs just induce proliferative IL-2 mRNA production
(Fig. 1). These data are in accordance with previous results
showing that, in both mice and rats, CD28SAbs induced a
polyclonal IL-2-dependent T cell activation, without inﬂamma-
tory adverse effects24. The upregulation of pro-inﬂammatory
cytokines and chemokines by hCD28 stimulation was particularly
relevant in the context of autoimmune diseases, such as MS and
T1D, where we recently evidenced that CD28 stimulation by
agonistic Abs strongly upregulated IL-8, IL-6, and IL-17A
expression and production9,10. These data were in contrast to
those obtained in multiple mouse models of autoimmune and
inﬂammatory diseases, where CD28 pro-inﬂammatory effects
were absent and CD28SAbs induced Treg cell activation and
clinical improvement11. Moreover, the comparison of the efﬁcacy
of CD28SAb in expanding Treg cells between human and mouse
clearly demonstrate that hCD28 is equally efﬁcient than mouse
(Fig. 2a). These data are consistent with the recent observation by
He et al. that CD28 stimulation by agonistic and in a stronger
manner by superagonistic Abs mediates ex vivo expansion of
human Treg26. The ability of hCD28 stimulation to expand Treg
cells has been supported by several data showing that also the
natural ligands B7.1/CD80 and B7.2/CD86 enhanced Treg
expansion27,28. However, the increase of Treg cells induced by
hCD28 natural ligands, agonistic, or superagonistic Abs is not
able to efﬁciently suppress CD28 pro-inﬂammatory functions as
evidenced by our data in both healthy, MS and T1D subject9.
Thus, the return of CD28-superagonistic Ab TGN1412 to the
clinic Phase I as TAB0829, on the basis of the recent ﬁndings that
low doses of TAB08 (0.015 μg ml-1) increased the number of
activated Treg cells without affecting pro-inﬂammatory cytokine
production30, must be really cautious. For instance, recent data
from Weissmuller et al. evidenced that TGN1412 administration
to a humanised mouse model induced strong lymphopenia, pro-
inﬂammatory cytokine production, and death within 2–6 h31.
One possible explanation for the strong pro-inﬂammatory
response elicited by human CD28SAb stimulation has be related
to a different balance between naïve and effector/memory T cells
in human vs. mouse16,17. However, we did not ﬁnd any sig-
niﬁcant differences in pro-inﬂammatory cytokine mRNA levels
between naïve vs. effector/memory CD4+ T cells upon stimula-
tion of hCD28 with either agonistic or superagonistic Abs
(Fig. 2b–f). These data are consistent with the results from
Waibler et al. showing that no differences were observed in Ca2+
release between human CD4+/CD45RA+ naïve vs. CD4+
/CD45RO+ memory T lymphocytes stimulated with CD28SAb14.
Thus, hCD28 pro-inﬂammatory functions are independent of the
differentiation status of T cells, but represent a signalling sig-
nature of the human costimulatory receptor.
The signalling capability of CD28 relies on its short cyto-
plasmic tail that has no enzymatic activity but contains three
highly conserved binding motifs (a N-terminal YMNM and two
proline-rich motifs), which are crucial for the activation of
downstream signalling cascade2. In particular, the C-terminal
proline-rich motif is a master regulator of CD28 signalling
functions, by binding the SH3 domain of several biochemical
partners2,32,33. The greater role of C-terminal proline-rich motif
is, however, the activation of NF-κB3,33, and one of the main
differences in the signalling functions of the C-terminal proline-
rich motif between human and mouse CD28 may be related to its
autonomous TCR-independent ability in activating NF-κB2.
Although, Watanabe et al. reported that the substitution of both
proline residues within the C-terminal P206YAPA210 motif of
mouse CD28 strongly reduced TCR-mediated NF-κB transcrip-
tional activity34, no data on the ability of this motif to regulate
CD28 autonomous signals activating NF-κB have been analysed
in the mouse system. By contrast, human C-terminal
P208YAPP212 motif mediates the recruitment of Filamin-A and
associated NIK8 to CD28, thus favouring NF-κB-dependent gene
expression6. Herewith, we extend these data by identifying the
P212, within the C-terminal proline-rich motif of hCD28
(PYAPP212), as a critical residue for hCD28-induced NF-κB
activation (Fig. 4) and pro-inﬂammatory functions (Fig. 3), as
well as for CD28 costimulatory signals integrating those delivered
by TCR for inducing NF-AT transcriptional activation and IL-2
gene expression (Supplementary Fig. 5). Interestingly, mouse
CD28 displays a natural substitution of this residue (A instead P)
and lack the ability to activate NF-κB (Fig. 4h) and pro-
inﬂammatory cytokines (Fig. 1). The reconstitution of the P
residue within mouse CD28 (mCD28A210P) strongly upregu-
lated CD28-induced NF-κB transcriptional activity (Fig. 4i), tyr-
osine phosphorylation (Fig. 4l), and cytokine gene expression
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(Fig. 4m). Moreover, since this P residue does not affect the
proline consensus motif (PYAP) of CD28, the C-terminal pro-
line-rich motif of hCD28 likely contains other consensus
sequences involved in the recruitment of pivotal signalling part-
ners regulating its selective pro-inﬂammatory functions.
The results from ex vivo co-precipitation experiments in either
human or mouse primary CD4+ T cells stimulated with B7.1/
CD80 expressing APC revealed important differences. Vav1, a
Rho/Rac guanine nucleotide exchange factor, that regulates sev-
eral aspect of T cell activation35 and that we have previously
found as a critical molecule coupling the C-terminal PYAPP of
hCD28 to the activation of downstream signalling pathways6,8,
co-precipitated with CD28 in both human and mouse primary
CD4+ T cells. On the contrary, Nck, an adaptor molecule that
plays a crucial role in the actin polymerisation and cytoskeleton
reorganisation processes required for cell polarisation, migration,
and signal transduction18, co-precipitates with human, but not
mouse CD28 (Fig. 5). Thus, the natural P to A substitution in
mouse CD28 (YAPA210) may be responsible for the loss of a
tyrosine-based consensus sequence binding for the SH2 domain
of Nck. For instance, we have previously demonstrated that tyr-
osine residues Y207 and Y209 within the C-terminal proline-rich
motif of CD28 are important for both cytoskeleton reorganisation
and NF-κB activation8. Interestingly, recent combinatorial pro-
teomic data from Tian et al. evidenced that Y209 together with
Y191 within the YMNM motif is an abundant phosphotyrosine
site and its phosphorylation depends on CD28/B7 interaction36.
Consistently, we found that Y209F mutation induces a strong
reduction of CD28 tyrosine phosphorylation, without affecting
the tyrosine phosphorylation of Y191 as demonstrated by the
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unaffected co-precipitation of p85 subunit of PI3K that depends
on tyrosine phosphorylated Y191MNM motif37 (Supplementary
Fig. 9). However, among the 28 proteins that bind CD28 in a
phosphotyrosine-dependent manner, the interactome analysis
failed to detect an interaction of CD28 with Nck. One possible
explanation for this discrepancy may be due to the different
experimental system used in the CD28 interactome analysis. Data
from Tian et al. were, indeed, obtained upon stimulation of Jurkat
cells with SEE-pulsed APC, where both TCR and CD28 were co-
engaged. In this experimental condition, CD28 may recruit dif-
ferent signalling mediators compared to CD28 stimulation alone.
For instance, when TCR is engaged, Nck can be recruited to TCR
by either a direct Nck association with CD3ε38,39 or via LAT/SLP-
7623. An interesting issue would be to compare the interaction
proﬁles of CD28 binding proteins in the presence or absence of
TCR engagement. Alternatively, a CD28-binding and Nck-
binding partner may function as a linker, thus favouring CD28/
Nck interaction.
Nck is composed of one SH2 and three SH3 domains involved
in protein–protein interaction. More than 60 binding partners of
Nck have been identiﬁed in several cell types, including Vav1. A
direct association of Vav1 and Nck has been described in T
lymphocytes as essential for optimal cytoskeleton remodelling20
and Vav1/Nck complexes can be recruited to TCR by either a
direct Nck association with CD3ε38,39 or via SLP-7623. On the
basis of the consensus sequences identiﬁed as optimal binding
sites for the SH2 of Nck18 and Vav119, the phosphorylated
Y209APP212 within the C-terminal proline-rich motif of CD28
may likely represent an optimal binding site for Nck and Vav1.
For instance, either Vav1 or Nck were able to associate with
hCD28 when expressed alone (Supplementary Fig. 8a, b). How-
ever, our data on the co-precipitation of CD28 with Nck, but not
Vav1, when Nck and Vav1 were co-expressed (Supplementary
Fig. 8c), as well as confocal data showing that the SH2 domain of
Nck, but not the SH2 domain of Vav1, was required for actin
polymerisation, Nck and Vav1 recruitment (Figs. 8, 9) support a
role for Nck in linking hCD28 to the cytoskeleton reorganisation
events necessary for the activation of downstream signalling
pathways and biological functions. For instance, an Nck R311K
mutant within the SH2 domain strongly inhibited CD28-
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mediated pro-inﬂammatory and costimulatory signalling prop-
erties (Fig. 10). Since Nck and Vav1 are both required for the
recruitment and activation of WASP/Arp2–3 complexes and
actin reorganisation23,40, the inability of mouse CD28 to recruit
Nck may account for the signalling difference observed between
human and mouse CD28 when engaged independently of TCR.
However, also SLP76 is required for recruitment of the Nck/
Vav1-WASp complex, via the Nck SH2 domain, and actin reor-
ganisation41 and the cooperation of CD28 with SLP-76 and Vav1
in a TCR-independent manner has been previously described42.
Interestingly, SLP-76 has been identiﬁed among the preferential
binding proteins of CD28 PpYAPP motif36. Experiments are in
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Fig. 10 Nck SH2 domain and actin polymerisation are required for CD28-mediated signalling properties. a NF-κB luciferase activity of CH7C17 cells
expressing hCD28WT transfected with empty vector (Vec) or HA-Nck R311K construct and stimulated in the presence (B7) or absence (Med) of Dap3/B7
cells. The results are expressed as the mean of luciferase units ± SD after normalisation to GFP expression. Asterisks (***) indicate p < 0.001 calculated by
Student’s t-test compared to B7-stimulated cells transfected with empty vector. Anti-HA western blotting was performed on total lysates (insert panel).
The results are representative of three independent experiments. b Primary CD4+ T cells were transfected with 2 μg of empty vector (Vec) or HA-Nck
R311K construct. Real-time PCR was used to measure IL-8 mRNA levels after stimulation with isotype control (Ig) or 2 μg ml−1 crosslinked anti-CD28.2
Abs. Data are expressed as arbitrary units (AU). Bars show the mean ± SD of four independent transfections. Anti-HA western blotting were performed on
total lysates (insert panel). c–f Human primary CD4+ T cells were stimulated for 6 h with isotype control mAb (Ig) or 2 μgml−1 crosslinked agonistic
CD28.2 (c, d) or superagonistic ANC28.1 Abs (e), or 2 μgml−1 crosslinked anti-CD3 (UCHT1) plus anti-CD28 (CD28.2) Abs (f) in the presence of 10 μM
cytochalasin D or DMSO, as vehicle control. IL-8 (c), IL-6 (d, e), and IL-2 (f) mRNA levels were measured by real-time PCR and values, normalised to
GAPDH, expressed as arbitrary units (AU). Lines represent mean values ± SD. g NF-AT luciferase activity of hCD28 WT cells transfected with empty
vector or HA-Nck R311K mutant and stimulated with medium (Med) or 5-3.1/B7 cells pre-pulsed or not (B7) with SEB (1 μg ml−1) in the presence of
DMSO, as vehicle control, or cytochalasin D. The results are expressed as the mean of luciferase units ± SD after normalisation to GFP values. *p < 0.05,
**p < 0.01, ***p < 0.001 calculated by Student’s t-test. All data are representative of three independent experiments
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progress to verify this issue and to better characterise the mole-
cular basis and the dynamic of CD28/Nck association. Moreover,
we cannot exclude that other critical residues may contribute to
the different CD28 signalling capabilities observed between
human and mouse. Recent data from Sanchez-Lockhart et al.
evidenced that, in unstimulated mouse T cells, CD28 has a weak
binding afﬁnity for B7.1/CD8043. Consistently, mouse CD28
exhibits a low ability to form conjugates with B7.1/CD80-
expressing cells (Supplementary Fig. 6b). Since, human and
mouse CD28 share only a 65% of identity in the extracellular
domain, an additional contribution of the extracellular domain
below human and mouse CD28 stimulation cannot be excluded.
The identiﬁcation of P212 within the C-terminal motif of
hCD28 as a critical residue for CD28 pro-inﬂammatory and
signalling functions not only opens a question for the use of
rodents as model for the study of CD28-mediated functions and
for the safety of new therapeutic approach, but also suggests a
deeper investigation of CD28 single-nucleotide polymorphisms,
some of which have been already linked to autoimmune dis-
orders, like Bechet’s disease44 and rheumatoid arthritis45. Recent
data from Hui et al.46 and Kamphorst et al.47 evidenced a
dominant role of CD28 for efﬁcient PD-1 therapy in cancer and
chronic viral infections. Interestingly, a C/G single-nucleotide
polymorphism (rs770610915) that causes a P212 to A212 missense
substitution has been recently identiﬁed in hCD28. It would be
interesting to analyse the presence of this polymorphism in
tumour patients that do not respond to anti-PD-1/PD-Ll therapy.
Methods
Cells and reagents. Human primary CD4+ T cells were enriched from PBMCs by
negative selection using a MACS microbead sorting kit (#130-096-533, Miltenyi
Biotec, Milan, Italy) and cultured in RPMI 1640 supplemented with 5% human
serum (Euroclone, UK), L-glutamine, penicillin, and streptomycin. The purity of
the sorted population was 95–99%, as evidenced by staining with anti-CD3 plus
anti-CD4 Abs (Supplementary Fig. 10). Human naïve CD45RA+ and effector
CD45RO+ were enriched from puriﬁed CD4+ T cell by positive and negative
selection, respectively, using a MACS anti-Phycoerythrin (PE) microbeads sorting
kit (#130-090-57, 1:10 dilution, Miltenyi Biotec, Milan, Italy) after labelling with a
PE-conjugated anti-CD45RA primary antibody (#130-098-184, 1:10 dilution,
Miltenyi Biotec, Milan, Italy). PBMCs were derived from buffy coats obtained from
anonymous healthy blood (HD) donors provided by the Immunohematology and
Transfusional Centre of Policlinico Umberto I (Sapienza University of Rome,
Italy). Written informed consent was obtained from blood donors and both the
informed consent form and procedure was approved by the Ethics Committee of
Policlinico Umberto I.
Mouse primary CD4+ T cells were enriched from spleen of C57BL/6 wild-type
mice (females of 8–10 weeks) by negative selection using a MACS microbead
sorting kit (#130-104-454, Miltenyi Biotec, Milan, Italy) and cultured in RPMI
1640 supplemented with 5% foetal bovine serum (FBS, Euroclone, UK), L-
glutamine, penicillin, and streptomycin. The purity of the sorted population was
92–95%, as evidenced by staining with anti-CD4 Abs (Supplementary Fig. 11).
Mice were bred and housed under speciﬁc pathogen-free conditions and
euthanised by CO2 inhalation. The studies involving animals have been conducted
in accordance with the Italian national guidelines for use and care of experimental
animals, established in D.Lgs. n.26/2014, and with European Directive 2010/63/UE.
The animal protocols have been approved by the Ethical Committee of the
Department of Molecular Medicine (Sapienza University of Rome, Italy). Sample
sizes were chosen to assure reproducibility of the experiments in accordance with
the principles of ethics regulation.
Murine EL-4 T cell line48 was kindly provided by Polly Matzinger (National
Institutes of Health, Bethesda, Maryland, USA) and was maintained as described
above. CD28-negative Jurkat T cell line CH7C1749 was kindly provided by
Frederique Michel (Pasteur Institute, Paris, France) and maintained as described
above with the addition of 400 µg ml−1 hygromycin B and 4 µg ml-1 puromycin
(Sigma-Aldrich, Milan, Italy). The CH7C17 Jurkat cell line has been used because
CD28-negative and easly transfectable with the CD28 mutants used in the study.
CH7C17 cells, stable transfected with hCD28 WT or hCD28P212A or hCD28
Y209FP212A mutants, mCD28 WT, or chimera CD28 WT, or chimera CD28 A210P
or EL-4 cells stable transfected with hCD28 WT were generated as previously
described8. Brieﬂy, stable transfectants were obtained by electroporating (at 260 V,
960 µF) 107 CH7C17 cells or EL-4 cells in 0.5 ml of RPMI 1640 supplemented with
20% FCS with 30 µg of constructs encoding CD28WT, or CD28 mutants. After 48
h, cells were placed in 96-well culture plates in selective RPMI 1640 medium
containing 2 mgml−1 G418 (Sigma). All cell lines expressed comparable levels of
CD28 (Supplementary Fig. 12). Murine L cells transfected with human B7.1/CD80
(Dap3/B7)50, HLA-DRB1*0101 (5-3.1)51, and 5-3.1 co-transfected with B7.1/CD80
(5-3.1/B7)52 were kindly provided by Robert Lechler and Giovanna Lombardi
(King’s College London, UK). These cells have been used because several studies
performed by our group evidenced that this experimental model perfectly mimics
the physiological CD28/B7 encounter and stimulation in both human T cell lines
and primary T lymphocytes. The mouse macrophage cell line RAW 264.7
expressing the murine B7.1 (ECACC, Salisbury, UK) was cultured in DMEM
supplemented with 10% FBS (Euroclone, UK), L-glutamine, penicillin, and
streptomycin.
The following antibodies were used: mouse anti-hCD28 (CD28.2, #555726, 2 μg
ml−1), mouse anti-human CD3 (UCHT1, #555330, 2 μg ml−1), goat anti-mouse
(GAM, #553998, 2 μgml−1), hamster anti-mouse CD28 (37.51, #553294, 2 μgml−1),
hamster anti-mouse CD3 (145-2C11, #553057, 2 μg ml−1), anti-human CD28-PE
(#555729, 1:10 dilution), anti-human CD3-PE (#555333, 1:10 dilution), anti-mouse
CD28-PE (#553297, 1:10 dilution), anti-mouse CD4-APC (#553051, 1:150
dilution), anti-mouse CD44-FITC (#553133, 1:100 dilution), anti-mouse CD62L-
PE (#553151, 1:150 dilution) (BD Biosciences, Milan, Italy); superagonistic anti-
human CD28 (ANC28.1, #177820, 2 μg ml−1) (Ancell, MN, USA); superagonistic
anti-mouse CD28 (D665, #LS-C58166, 2 μg ml−1) (LifeSpan BioSciences, USA);
rabbit anti-hamster (#A18891, 2 μg ml−1 ThermoFisher Scientiﬁc, CA, USA); anti-
human CD4-APC (#130091232, 1:10 dilution), anti-human CD80-PE
(#130099200, 1:10 dilution); anti-mouse CD80-FITC (#104705, 1:10 dilution)
(BioLegend, CA, USA); anti-human CD45RA-FITC (#21819453, 1:10 dilution),
anti-human CD45RO-FITC (#21336453, 1:10 dilution) (Immunotools, Germany);
goat anti-CD28 (N-20, #sc-1624, 1:400 dilution), rabbit anti-Vav (H-110, #sc-
33109, 1:400 dilution), rabbit anti-HA (Y-11, #sc-805, 1:400 dilution), mouse anti-
HA (F-7, #sc-7392) (Santa Cruz Biotechnology, CA); anti-PI3K pan-p85 (#06-497,
1:500 dilution), rabbit anti-Nck (#06-228, 1:500 dilution) (Merck-Millipore, Italy);
anti-c-myc (9E10, #1166719001, 1:1000 dilution, Roche). Staphylococcal
Enterotoxin B (SEB, BT202) was purchased by Toxin Technology Inc. (Sarasota,
FL, USA) and used at 1 μg ml−1.
Plasmids cell transfection and luciferase assays. The expression vector mouse
CD28 WT (mCD28) was obtained from a PCR fragment (684 bp) cloned as a Bam
HI/Not I fragment into the βCDNA4 vector (J. Nunès, Marseille, France). The pEF-
Bos construct expressing hCD28 WT (hCD28 WT) has been previously described6.
The hCD28P212A and hCD28Y209FP212A mutants in the C-terminal proline-rich
motif were derived from hCD28 WT by PCR. The hCD28P212A was generated by
PCR introducing the P212A substitution into hCD28WT by two-step PCR
mutagenesis with the following oligonucleotides: 5′-CTATGCCCCAGCACGCGA
CTTC-3′ and 5′-GAAGTCGCGTGCTGGGGCATAG-3′; the hCD28Y209FP212A
was generated by PCR introducing the Y209F substitution into hCD28P212A by
two-step PCR mutagenesis with the following oligonucleotides: 5′-CATTACCAG
CCCTTTGCCCCA-3′ and 5′-TGGGGCAAAGGGCTGGTAATGCTT-3′.
The βCDNA4 construct expressing mouse CD28 mutant A210P within the
C-terminal proline-rich motif of mCD28 was generated by PCR introducing the
A210P substitution into mCD28WT by two-step PCR mutagenesis with the
following oligonucleotides: 5′-CTACGCCCCTCCCAGAGACTTTG-3′ and
5′-CAAAGTCTCTGGGAGGGGCGTAG-3′. The chimeric CD28 molecules
containing the extracellular and transmembrane domain of hCD28 and the
cytoplasmic tail of mouse CD28 WT (chimera CD28 WT) or mouse CD28 mutant
A210P (chimera CD28 A210P) were generated as described by PCR and cloned in
BamH1 and Not I restriction sites of βCDNA4 vector. The following
oligonucleotides were used: 5′-CCTGGATCCAGGACAAAGATGCTCAGGCTG-3′,
5′-ACAGTGGCCTTTATTATTGTTATCTGGACAAATAGTAGAAGGAACA
GA-3′, 5′-TCTGTTCCTTCTACTATTTGTCCAGATAACAATAATAAA
GGCCACTGT-3′, and 5′-GAGGTGCCGTAAAGCACTAAATCGGAAC-3′. The
entire sequence of the mutants was veriﬁed by DNA sequencing. Stable
transfectants were obtained by electroporating (at 260 V, 960 μF) 107 CH7C17 cells
in 0.5 ml of RPMI 1640 supplemented with 20% FCS with 30 μg of pEFBos-neo
encoding hCD28 WT, or hCD28 mutants or βCDNA4 encoding mCD28 WT.
After 48 h, cells were placed in 96-well culture plates in selective RPMI 1640
medium containing 2 mg ml-1 G418 (Sigma-Aldrich). Transfectants were subjected
to cell sorting by FACScan (BD Biosciences, San Jose, CA) to obtain stable cell lines
expressing similar levels of CD28.
pEF-Bos expressing C-terminal myc-tagged Vav1 was previously described6.
The substitution of Vav1 (R696A) mutant was derived from C-terminal
myc-tagged Vav1 by PCR. The oligonucleotides used were: 5′-ACTTTCTTGG
TGGCGCAGAGGGTGAAG-3′ and 5′-CTTCACCCTCTGCGCCACCAAG
AAAGT-3′. All oligonucleotides were purchased by Euroﬁns Genomics (Edersberg,
Germany).
Cherry and GFP constructs were generated by cloning Vav1 and Vav1 R696A
mutant in Eco-RI and Bam HI restriction sites of pm-Cherry-C1 and pEGFP-N1
expression vectors (Clontech, UK), respectively. The sequence of Vav1 constructs
were veriﬁed by DNA sequencing. The NF-κB luciferase gene under the control of
six thymidine kinase NF-κB sites53 was kindly provided by J.F. Peyron (Centre
Méditerranéen de Médecine Moléculaire, Nice, France). The NF-AT luciferase
reporter construct containing the luciferase gene under the control of the human
IL-2 promoter NF-AT binding site54 was kindly provided by C. Baldari (University
of Siena, Siena, Italy).
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GFP-Nck WT, GFP-Nck R311Q, and GFP-Nck W149K mutant constructs were
provided by A. Borroto (Madrid, Spain). HA-Nck WT and HA-Nck R311K mutant
constructs were provided by Wei Li (University of Southern California, Los
Angeles, CA, USA).
Primary CD4+ T cells, suspended in 100 μl of Nucleofector solution (VPA-
1002, Amaxa Biosystems), were electroporated with 1 μg of the indicated
expression vector using the V-024 programme of the Nucleofector.
For luciferase assays, 107 cells were electroporated (at 260 V, 960 µF) in 0.5 ml
RPMI 1640 supplemented with 20% FCS with 2 μg NF-κB luciferase or 10 μg NF-
AT luciferase together with 5 μg pEGFP and each indicated expression vector,
keeping the total amount of DNA constant (40 µg) with empty vector. 24 h after
transfection, cells were stimulated with Dap3 or Dap3/B7 or 5-3.1 or 5-3.1/B7 cells
pre-pulsed with SEB (1 μg ml−1) at 37 °C for 6 h. Luciferase activity was measured
according to the manufacturer’s instruction (#E1500, Promega). Luciferase activity
determined in triplicates was expressed as arbitrary luciferase units after
normalisation to GFP values.
Immunprecipitations and immunoblotting. Primary CD4+ T cells and Jurkat
cells were stimulated as indicated at 37 °C. At the end of incubation, cells were
harvested and lysed for 30 min on ice in 1% Nonidet P-40 lysis buffer (150 mM
NaCl, 20 mM Tris-HCl (pH 7.5), 1 mM EGTA, 1 mM MgCl2, 50 mM NaF, 10 mM
Na4P2O7) in the presence of inhibitors of proteases and phosphatases (10 μg ml−1
leupeptin, 10 μg ml−1 aprotinin, 1 mM NaVO4, 1 mM pefablock-SC). Extracts were
precleared for 1 h with Protein-A (Amersham) or Protein G Sepharose beads
(Sigma-Aldrich) and then immunoprecipitated for 2 h with the human anti-CD28
Abs (CD28.2, 2 μg per immunoprecipitation) pre-adsorbed on Protein-G Sephar-
ose beads (20 μl per immunoprecipitation) or rabbit anti-hamster Abs (2 μg per
immunoprecipitation) pre-adsorbed on Protein-A Sepharose beads (20 μl per
immunoprecipitation) further incubated with mouse anti-CD28 (37.51, 2 μg per
immunoprecipitation). Proteins were resolved by SDS-PAGE and blotted onto
nitrocellulose membranes. Blots were incubated with the indicated primary anti-
bodies, extensively washed and after incubation with horseradish peroxidase
(HRP)-labelled goat anti-rabbit (#NA934V, 1:5000 dilution) or HRP-labelled goat
anti-mouse (#NA931V, 1:5000 dilution) (Amersham), or (HRP)-labelled donkey
anti-goat Abs (#sc-2033, 1:5000 dilution) (Santa Cruz Biotechnology) developed
with the enhanced chemiluminescence’s detection system (GE Healthcare).
Uncropped version of all Western blots can be found in Supplementary Figs. 14
and 15.
Cytokine production. Secretion of IL-8 was measured from the supernatants of
CD4+ T cells cultured for 24 h in ﬂat bottom 48 culture wells (3 × 105 cells per
well) either unstimulated or stimulated with crosslinked anti-CD28.2 Ab
(2 μg ml−1) or adherent Dap3/B7 cells ﬁxed with paraformaldehyde to avoid
detachment and secretion. A cytometric bead-based immunoassay (#558277, CBA
FLEX SET, BD Biosciences) was used to measure IL-8. Data were analysed with the
FCAP Array v3.0.1 software (Soft Flow Hungary Ltd.).
Real-time PCR. Total RNA was extracted using Trizol (Thermo Fisher Scientiﬁc,
CA, USA) from 2 × 106 cells and RNeasy MicroKit (#74004, Qiagen) from 5 × 105
cells according to the manufacturer’s instructions and was reverse-transcribed into
cDNA by using Moloney murine leukaemia virus reverse transcriptase (Invitro-
gen). TaqMan Universal PCR Master Mix, human: IL-8, IL-2, IL-6, IFN-γ, TNF,
IL-1β and endogenous GAPDH, mouse: IL-2, IL-6, IFN-γ, TNF and endogenous
RLP32 primer/probe sets were purchased from Applied Biosystems. The relative
quantiﬁcation was performed using the comparative CT method. The median value
of human or mouse CD4+ T cell stimulated with control isotype matched Abs was
used as CT calibrator in all comparative analyses.
Confocal microscopy. 15 × 103 murine Dap3/B7 or RAW 264.7 cells were adhered
on cover glasses (12 mm) overnight at 37 °C. CH7C17 cells expressing hCD28 WT,
or mCD28 WT, or CD28P212A mutant, or chimera CD28 WT, or chimera CD28
A210P mutant were transfected for 24 h with 20 μg of GFP or cherry constructs,
seeded on cover glasses for 15 min at 37 °C, ﬁxed by 2% paraformaldehyde and
permeabilised by 0.1% saponin in PBS containing 1% BSA. Filamentous actin (F-
Actin) was stained by using phalloidin-633 (#A22284, 1:75 dilution, Molecular
Probes). Confocal observations were performed using a Leica DMIRE (Leica
Microsystems, Heidelberg, Germany) and a Zeiss LSM 780 (Zeiss, Berlin,
Germany). Images were analysed with the Adobe® Photoshop® programme. The
relative recruitment index (RRI) was calculated as previously described by the
formula: RRI= [mean ﬂuorescence intensity (MFI) at synapse−background]/[MFI
at all the cell membrane not in contact with APC−background]. At least 15 cells or
conjugates were examined quantitatively for each experiment. Statistical sig-
niﬁcance was calculated using a Student’s t-test. Signals from different ﬂuorescent
probes were taken in parallel. Several cells were analysed for each labelling con-
dition, and representative results are presented.
Measurement of conjugate formation. Conjugate formation was measured as
previously described6. Brieﬂy, CH7C17 Jurkat cells expressing hCD28 WT, or
mCD28 WT or CD28 mutants were transfected with pEGFP construct and
transfectants (3.5 × 106) were incubated for 5 min at 37 °C with Dap3/B7 (1.2 ×
106) or RAW-264.7 cells in a ﬁnal volume of 70 μl of RPMI, then diluted in 500 μl
RPMI and analysed by FACS. Conjugates were identiﬁed on a total of 105 GFP-
positive events by gating for SSC and FSC and expressed as mean percentage ± SD
of triplicate samples. An example of the gating strategy used is reported in
Supplementary Fig. 13.
Statistical analysis. The sample size was chosen based on previous studies to
ensure adequate power. Parametrical statistical analysis (mean and SD) was per-
formed to evaluate differences between continuous variables through Prism 5.0
(GraphPad Software, San Diego, CA) using standard unpaired t-test. For multiple
group comparisons, signiﬁcant differences were calculated using the nonparametric
Mann–Whitney U test, and linear regression analyses were performed using the
Pearson chi-squared test. For all tests, p-values < 0.05 were considered signiﬁcant.
Study design. Sample sizes were determined based on similar previous studies. No
samples or animals were excluded from analysis. No blinding or randomisation
was used during the experiments.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request.
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